Ehlers-Danlos Syndrome Overview

Ehlers-Danlos syndrome (EDS) comprises a group of genetic disorders affecting connective tissue resulting in abnormal skin fragility, joint hypermobility, and tissue extensibility. The condition results from defects in collagen synthesis, processing, or structure. Clinical manifestations vary widely depending on EDS type, from mild skin findings to life-threatening vascular complications. Understanding the different types and clinical manifestations helps enable appropriate management and surveillance for serious complications that may not be immediately apparent.

Skin Manifestations and Features

Skin in EDS is characteristically velvety, hyperextensible, and fragile. Patients bruise easily and show poor wound healing with thin, atrophic scars. Easy bleeding from minor trauma is common. Striae (stretch marks) develop easily even with minor weight changes. Some EDS types show characteristic skin findings including translucent skin revealing underlying vasculature or unusual scarring patterns including papyraceous (thin, crinkled appearance) scars. Skin texture may be described as doughy or velvety. Skin manifestations vary depending on EDS type, with some types showing minimal skin involvement while others have obvious and dramatic skin changes.

Joint and Connective Tissue Involvement

Beyond skin, EDS affects joints and connective tissue throughout the body. Joint hypermobility is characteristic, predisposing to dislocation and chronic pain. Patients often show excessive flexibility in seemingly unusual ways. Fingers may bend backward excessively. Shoulders dislocate with minimal trauma. Chronic joint pain results from ongoing subluxations and inflammation. Flat feet or other foot deformities may develop. Scoliosis (curved spine) may develop and progress. Patients frequently develop early-onset osteoarthritis due to abnormal joint mechanics and tissue laxity.

Cardiovascular and Serious Complications

Cardiovascular complications including aortic dilation, aneurysm, and spontaneous vascular rupture occur in certain EDS types, particularly vascular EDS, creating life-threatening risks. Aortic root dilation may lead to dissection and rupture without warning. Spontaneous arterial rupture can occur with minimal trauma. Mitral valve prolapse is common. Patients with vascular EDS carry markedly increased mortality risk, particularly in adulthood. Gastrointestinal involvement may cause spontaneous perforation, which is life-threatening. Careful monitoring for vascular and gastrointestinal complications is essential in high-risk EDS types.

Systemic and Multisystem Involvement

Ocular involvement may include myopia, astigmatism, and retinal detachment. Neurological involvement in some EDS types causes progressive symptoms including headaches, neurological decline, and structural abnormalities of brain or spinal cord. Dental problems including malocclusion and loose teeth may develop. Hearing loss can occur. Skin and tissue fragility may affect surgical healing and cause complications after procedures. Affected individuals require comprehensive evaluation for all potential system involvement to enable appropriate surveillance and prevent serious complications.

Diagnosis, Classification, and Genetics

EDS is classified into 13 types based on genetic mutations and clinical features, with classification revised in 2017. Diagnosis relies on clinical presentation, family history, and in many cases, genetic testing confirming specific mutations. Different EDS types show different inheritance patterns, with most autosomal dominant but some autosomal recessive. Collagen analysis or protein testing may aid diagnosis in certain types. Understanding the specific EDS type helps guide surveillance and management strategies, as different types carry different risks for serious complications.

Management, Support, and Quality of Life

Management focuses on preventing injury through lifestyle modifications and protection from trauma. Wound care should emphasize meticulous technique given poor healing. Cardiovascular surveillance including imaging is essential in types with vascular involvement. Genetic counseling helps families understand inheritance patterns. Multidisciplinary care involving dermatology, rheumatology, cardiology, and orthopedics optimizes outcomes. Living with EDS creates psychological burden from chronic disease, visible skin changes, functional limitations, and ongoing medical complications. Depression and anxiety are common in EDS patients. Support groups and counseling help individuals cope with the chronic disease and manage the significant lifestyle limitations imposed by EDS.

Frequently Asked Questions

Is EDS inherited? EDS is autosomal dominant or recessive depending on type; genetic counseling helps determine inheritance.

Will my child be disabled? Severity varies widely by EDS type; some individuals have minimal morbidity while others experience significant limitations.

What about vascular complications? Certain EDS types carry risk of serious vascular complications; surveillance helps detect and treat them.

Are there treatments? No cure exists; management focuses on preventing complications and surveillance.

How is EDS monitored? Regular surveillance including cardiovascular imaging, ophthalmology, and orthopedic evaluation helps detect complications early.

References

  1. Paller AS, Mancini AJ. Hurwitz Clinical Pediatric Dermatology. 5th ed. Elsevier; 2016.
  2. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8-26.
  3. Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 6th ed. Elsevier; 2016.
  4. Castori M, Voermans NC. Neurological manifestations of Ehlers-Danlos syndromes. Nat Rev Neurol. 2016;12(1):30-42.
  5. Fikree A, Gtonidis M, Aziz Q, et al. Gastrointestinal involvement in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):181-187.
  6. Castori M, Colombi M, Voermans NC, et al. The 2017 classification of Ehlers-Danlos syndrome. J Orofac Orthop. 2018;79(6):413-422.
  7. Colombi M, Dordoni C, Venturi G, et al. Molecular abnormalities of type I and III collagens in patients with Ehlers-Danlos syndrome types I and III. J Invest Dermatol. 1992;99(2):225-230.
  8. Superti-Furga A, Steinmann B. Ehlers-Danlos syndrome. In: Emery and Rimoin's Principles and Practice of Medical Genetics. 6th ed. Elsevier; 2013.